MX2016012318A - Compuesto amidico. - Google Patents
Compuesto amidico.Info
- Publication number
- MX2016012318A MX2016012318A MX2016012318A MX2016012318A MX2016012318A MX 2016012318 A MX2016012318 A MX 2016012318A MX 2016012318 A MX2016012318 A MX 2016012318A MX 2016012318 A MX2016012318 A MX 2016012318A MX 2016012318 A MX2016012318 A MX 2016012318A
- Authority
- MX
- Mexico
- Prior art keywords
- amide compound
- receptor
- pharmaceutical composition
- antagonizing effect
- salt
- Prior art date
Links
- -1 Amide compound Chemical class 0.000 title abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Problema: Se presenta un compuesto que es útil como ingrediente activo de una composición farmacéutica, por ejemplo, una composición farmacéutica para tratar la insuficiencia renal crónica y/o la nefropatía diabética. Medio para Resolverlo: Los inventores de la presente han llevado a cabo extensos estudios sobre un compuesto con una acción antagonista del receptor EP4 y han encontrado que un compuesto amídico o una sal del mismo exhibe una acción antagonista del receptor EP4, completando de esa manera la presente invención. El compuesto amídico o una sal del mismo tiene acción antagonista del receptor EP4 y se lo puede utilizar como ingrediente activo de una composición farmacéutica para prevenir y/o tratar diversas enfermedades relacionadas con el EP4, por ejemplo, la insuficiencia renal crónica y/o la nefropatía diabética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014064590 | 2014-03-26 | ||
| PCT/JP2015/059026 WO2015147020A1 (ja) | 2014-03-26 | 2015-03-25 | アミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016012318A true MX2016012318A (es) | 2017-02-23 |
| MX368098B MX368098B (es) | 2019-09-19 |
Family
ID=54195532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012318A MX368098B (es) | 2014-03-26 | 2015-03-25 | Compuesto amidico. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10106523B2 (es) |
| EP (1) | EP3124480B1 (es) |
| JP (1) | JP6428763B2 (es) |
| KR (1) | KR20160138098A (es) |
| CN (1) | CN106132945B (es) |
| AR (1) | AR099833A1 (es) |
| CA (1) | CA2943778A1 (es) |
| ES (1) | ES2684334T3 (es) |
| MX (1) | MX368098B (es) |
| PL (1) | PL3124480T3 (es) |
| PT (1) | PT3124480T (es) |
| RU (1) | RU2684906C2 (es) |
| TW (1) | TW201623277A (es) |
| WO (1) | WO2015147020A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US20200069686A1 (en) | 2017-05-18 | 2020-03-05 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023853A1 (en) * | 2002-05-23 | 2004-02-05 | Peri Krishna G. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| CA2660133C (en) * | 2006-08-11 | 2015-10-27 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| US20110028463A1 (en) * | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| PH12013500467A1 (en) * | 2010-09-21 | 2013-04-29 | Eisai R&D Man Co Ltd | Pharmaceutical composition |
| WO2012103071A2 (en) * | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
-
2015
- 2015-03-24 TW TW104109378A patent/TW201623277A/zh unknown
- 2015-03-25 CA CA2943778A patent/CA2943778A1/en not_active Abandoned
- 2015-03-25 KR KR1020167027923A patent/KR20160138098A/ko not_active Abandoned
- 2015-03-25 JP JP2016510404A patent/JP6428763B2/ja not_active Expired - Fee Related
- 2015-03-25 MX MX2016012318A patent/MX368098B/es active IP Right Grant
- 2015-03-25 EP EP15770149.1A patent/EP3124480B1/en active Active
- 2015-03-25 AR ARP150100875A patent/AR099833A1/es unknown
- 2015-03-25 PL PL15770149T patent/PL3124480T3/pl unknown
- 2015-03-25 RU RU2016141650A patent/RU2684906C2/ru active
- 2015-03-25 PT PT15770149T patent/PT3124480T/pt unknown
- 2015-03-25 CN CN201580016273.8A patent/CN106132945B/zh not_active Expired - Fee Related
- 2015-03-25 US US15/127,574 patent/US10106523B2/en active Active
- 2015-03-25 ES ES15770149.1T patent/ES2684334T3/es active Active
- 2015-03-25 WO PCT/JP2015/059026 patent/WO2015147020A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3124480A1 (en) | 2017-02-01 |
| ES2684334T3 (es) | 2018-10-02 |
| CA2943778A1 (en) | 2015-10-01 |
| RU2684906C2 (ru) | 2019-04-16 |
| RU2016141650A3 (es) | 2018-11-12 |
| CN106132945B (zh) | 2019-04-26 |
| AR099833A1 (es) | 2016-08-24 |
| TW201623277A (zh) | 2016-07-01 |
| CN106132945A (zh) | 2016-11-16 |
| EP3124480A4 (en) | 2017-11-22 |
| PL3124480T3 (pl) | 2018-10-31 |
| JPWO2015147020A1 (ja) | 2017-04-13 |
| WO2015147020A1 (ja) | 2015-10-01 |
| JP6428763B2 (ja) | 2018-11-28 |
| PT3124480T (pt) | 2018-10-04 |
| RU2016141650A (ru) | 2018-04-27 |
| EP3124480B1 (en) | 2018-07-11 |
| KR20160138098A (ko) | 2016-12-02 |
| MX368098B (es) | 2019-09-19 |
| US20180030030A1 (en) | 2018-02-01 |
| US10106523B2 (en) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016012318A (es) | Compuesto amidico. | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| EA201391315A1 (ru) | Гуанидиновое соединение | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| GEAP201914546A (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| PH12014500887A1 (en) | Aminoalkyl-substituted n-thienyl benzamide derivative | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| TN2015000255A1 (fr) | Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| MX365021B (es) | Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |